BridgeBio PharmavsJohnson & Johnson

BBIO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BBIO

BridgeBio Pharma, Inc.

$77.36

Value $15.0B

-1.20%
BBIO's page

BridgeBio Pharma (BBIO) has a market value of $15.0B and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, BBIO moved +16.5% and JNJ +47.5%. Dividend yield: BBIO none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BBIO$15.0B

    JNJ$681B

    JNJ is 45 times BBIO

  • Revenue, 12 months

    BBIO$946M

    JNJ$99.3B

    JNJ is 105 times BBIO

  • Net income, 12 months

    BBIO-$566M

    JNJ$16.1B

  • Operating margin

    BBIO-38.5%

    JNJ–

  • ROIC

    BBIO-97.6%

    JNJ12.4%

    109.9 points apart

  • P/E

    BBIO–

    JNJ42.3

  • Dividend yield

    BBIO0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    BBIO+60.6%

    JNJ+98.6%

    38.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BBIO+60.6%

JNJ+98.6%

10020020222023202420252026
Returns by period
PeriodBBIOWith dividendsJNJWith dividends
1 year since November 14, 2025+16.5%Price +16.5%+47.5%Price +44.2%
3 years since November 16, 2023+168.1%+38.9% a yearPrice +168.1%+105.0%+27.0% a yearPrice +88.2%
5 years since November 15, 2021+60.6%+9.9% a yearPrice +60.6%+98.6%+14.7% a yearPrice +72.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BBIOBridgeBio PharmaJNJJohnson & Johnson

Valuation

BBIOJNJ
Valuation
Price$77.36$282.55
Market value$15.0B$681B
Enterprise value (EV)$16.1B$708B
P/E–42.3
P/E, 5-year median–21.9
P/B–8.4
EV/EBIT–39.9
Free cash flow yield–3.0%

Results and growth

BBIOJNJ
Results and growth
Revenue, 12 months$946M$99.3B
Net income, 12 months-$566M$16.1B
Free cash flow, 12 months-$370M$20.6B
Earnings per share, 12 months-$3.03$6.59
Revenue growth, year on year126.3%6.1%
Revenue growth a year, past+127.4%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

BBIOJNJ
Margins and returns on capital
Gross margin94.3%67.6%
Operating margin-38.5%–
Net margin-59.8%16.2%
ROIC-97.6%12.4%
ROE–19.7%

Balance sheet

BBIOJNJ
Balance sheet
Cash$1.5B$17.2B
Total debt$2.6B$44.7B
Net debt / EBITDA–1.1
Interest cover-7.1×18.0×

Dividends and buybacks

BBIOJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield0.3%0.9%
Shareholder yield0.3%2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BBIO or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, BridgeBio Pharma or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 45.4 times BridgeBio Pharma ($15.0B), at today's prices.

How did BBIO and JNJ stock do over the last 5 years?

Since November 15, 2021, BBIO's price moved +60.6% and JNJ's +72.8%. With dividends: BBIO +60.6% (+9.9% a year), JNJ +98.6% (+14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, BBIO or JNJ?

The dividend yield at today's price is none for BridgeBio Pharma and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, BridgeBio Pharma or Johnson & Johnson?

Over the last twelve months, the net margin was -59.8% for BridgeBio Pharma and 16.2% for Johnson & Johnson, and the operating margin -38.5% and –. Revenue was $946M and $99.3B.

Which is the better investment, BridgeBio Pharma or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.